Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

62.13
+0.50000.81%
Volume:1.11M
Turnover:68.74M
Market Cap:7.36B
PE:24.27
High:62.21
Open:61.93
Low:61.50
Close:61.63
52wk High:82.22
52wk Low:47.50
Shares:118.47M
Float Shares:116.00M
Volume Ratio:0.92
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.56
EPS(LYR):2.56
ROE:153.59%
ROA:22.24%
PB:150.79
PE(LYR):24.27

Loading ...

May 10, 2021

Major Issues Report

8-K - Current report
May 10, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 05, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 03, 2021

Major Issues Report

8-K - Current report
Mar 01, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 23, 2021

Major Issues Report

8-K - Current report
Feb 23, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 23, 2021

Major Issues Report

8-K - Current report
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 26, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 13, 2021

Major Issues Report

8-K - Current report
Jan 11, 2021

Major Issues Report

8-K - Current report
Dec 08, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 02, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]